📗 Cite This Artifact
Ventus Therapeutics
Overview
Ventus Therapeutics is a drug discovery company focused on developing novel small molecule therapeutics targeting innate immunity pathways, particularly the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and gasdermin proteins. The company's innovative approach to modulating pyroptosis and inflammatory cell death positions it uniquely in the neurodegenerative disease space.
Company Profile
| Attribute | Value |
|-----------|-------|
| Founded | 2018 |
| Headquarters | Cambridge, Massachusetts, USA |
| CEO | Dr. Juan Andres |
| Funding | Series B ($70M, 2023) |
| Focus | NLRP3 and gasdermin inhibitors |
| Stage | Preclinical |
Founding and Scientific Foundation
Ventus Therapeutics was founded based on research from leading academic institutions:
- Scientific founders: Dr. Thirumala-Devi Kanneganti (St. Jude Children's Research Hospital), Dr. Russell Vance (UC Berkeley)
- Research focus: Gasdermin biology and pyroptosis mechanisms
- Approach: Structure-based drug design targeting protein-protein interactions
The company's platform leverages cryo-EM structures of NLRP3 and gasdermins to design highly selective inhibitors.
Science and Technology
Dual-Target Platform
Ventus's platform targets two critical nodes in the inflammatory cascade:
This dual approach provides broader anti-inflammatory effects than single-target approaches.
Overview
Ventus Therapeutics is a drug discovery company focused on developing novel small molecule therapeutics targeting innate immunity pathways, particularly the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and gasdermin proteins. The company's innovative approach to modulating pyroptosis and inflammatory cell death positions it uniquely in the neurodegenerative disease space.
Company Profile
| Attribute | Value |
|-----------|-------|
| Founded | 2018 |
| Headquarters | Cambridge, Massachusetts, USA |
| CEO | Dr. Juan Andres |
| Funding | Series B ($70M, 2023) |
| Focus | NLRP3 and gasdermin inhibitors |
| Stage | Preclinical |
Founding and Scientific Foundation
Ventus Therapeutics was founded based on research from leading academic institutions:
- Scientific founders: Dr. Thirumala-Devi Kanneganti (St. Jude Children's Research Hospital), Dr. Russell Vance (UC Berkeley)
- Research focus: Gasdermin biology and pyroptosis mechanisms
- Approach: Structure-based drug design targeting protein-protein interactions
The company's platform leverages cryo-EM structures of NLRP3 and gasdermins to design highly selective inhibitors.
Science and Technology
Dual-Target Platform
Ventus's platform targets two critical nodes in the inflammatory cascade:
This dual approach provides broader anti-inflammatory effects than single-target approaches.
Mechanism in Parkinson's Disease
In Parkinson's disease, both NLRP3 activation and gasdermin-mediated pyroptosis contribute to dopaminergic neuron death:
Alpha-synuclein aggregation → Microglial NLRP3 activation → Caspase-1 activation
↓
Gasdermin D cleavage
↓
Pyroptotic cell death
↓
Dopaminergic neuron loss
Ventus's inhibitors block this pathway at multiple points, potentially providing enhanced neuroprotection.
Pipeline
Programs
| Program | Target | Indication | Stage | Status |
|---------|--------|------------|-------|--------|
| VTS-101 | NLRP3 | Parkinson's disease | Preclinical | Lead optimization |
| VTS-202 | Gasdermin D | Neurodegeneration | Discovery | Hit-to-lead |
| VTS-303 | NLRP3/Gasdermin | Inflammatory diseases | Discovery | Early stage |
VTS-101 (Parkinson's Disease)
VTS-101 is Ventus's lead program for Parkinson's disease:
- Mechanism: Direct NLRP3 inhibition (NACHT domain binding)
- Selectivity: >100-fold over related NLRs
- BBB penetration: Designed for CNS exposure; brain-to-plasma ratio >0.3
- Pharmacokinetics: Once-daily oral dosing potential
Preclinical data in 6-OHDA rat model showed:
- Reduced dopaminergic neuron loss in substantia nigra
- Decreased IL-1β and IL-18 in CSF
- Improved behavioral outcomes on cylinder test
- No signs of immunosuppression at effective doses
VTS-202 (Gasdermin Inhibitor)
VTS-202 targets gasdermin D, the effector protein of pyroptosis:
- Mechanism: Prevents gasdermin D N-terminal domain oligomerization
- Selectivity: Selective for GSDMD over GSDMA, GSDMB, GSDMC
- Rationale: Blocks downstream of NLRP3/caspase-1
This approach may provide benefit even when NLRP3 is partially active.
Funding and Partnerships
| Round | Amount | Year | Investors |
|-------|--------|------|-----------|
| Series A | $25M | 2019 | Versant Ventures, Third Rock |
| Series B | $70M | 2023 | Google Ventures, Andreessen Horowitz, ARCH Venture |
Academic Collaborations
- Harvard Medical School: Dr. Hao Wu - Inflammasome structural biology
- University of Michigan: Dr. Katherine Fitzgerald - Innate immunity
Competitive Advantages
Market Opportunity
The Parkinson's disease neuroinflammation market represents a significant opportunity:
| Parameter | Value |
|-----------|-------|
| Global PD patients | ~10 million |
| Target population | Early-to-mid stage patients with inflammation biomarkers |
| Market potential | $3-7B annually |
| Development timeline | 4-6 years to potential approval |
Competitive Landscape
Ventus competes with several companies in the NLRP3 space, but its gasdermin program provides a differentiated approach:
| Company | Focus | Differentiation |
|---------|-------|-----------------|
| Ventus | NLRP3 + Gasdermin | Dual mechanism |
| Olacteant | NLRP3 (Dapansutrile) | Clinical data |
| NodThera | NLRP3 | CNS expertise |
| IFM/BMS | NLRP3 | Big pharma resources |
| Novartis | NLRP3 (DFV890) | Phase 1 data |
Development Timeline
gantt
title Ventus Therapeutics PD Program
dateFormat YYYY
axisFormat %Y
section VTS-101
Lead optimization :active, 2023, 2025
IND-enabling :2025, 2026
Phase 1 :2026, 2027
Phase 2 :2027, 2029
section VTS-202
Hit-to-lead :active, 2024, 2025
Lead optimization :2025, 2026
IND-enabling :2026, 2027
References
See Also
- [NLRP3 Inflammasome Inhibitors for Parkinson's Disease](/mechanisms/nlrp3-inflammasome-inhibitors-parkinsons)
- [Pyroptosis Inhibition Therapy](/therapeutics/pyroptosis-inhibition-therapy)
- [NodThera Ltd.](/companies/nodthera)
- [IFM Therapeutics](/companies/ifm-therapeutics)
- [NLRP3 Inhibitors Investment Landscape](/investment/nlrp3-inflammasome)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | companies-ventus-therapeutics |
| kg_node_id | None |
| entity_type | company |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-c90615607928 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ventus-therapeutics'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-companies-ventus-therapeutics?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Ventus Therapeutics](http://scidex.ai/artifact/wiki-companies-ventus-therapeutics)
http://scidex.ai/artifact/wiki-companies-ventus-therapeutics